Featured Publications
Spatial profiling of gastric cancer patient-matched primary and locoregional metastases reveals principles of tumour dissemination
Sundar R, Liu D, Hutchins G, Slaney H, Silva A, Oosting J, Hayden J, Hewitt L, Ng C, Mangalvedhekar A, Ng S, Tan I, Tan P, Grabsch H. Spatial profiling of gastric cancer patient-matched primary and locoregional metastases reveals principles of tumour dissemination. Gut 2020, 70: 1823-1832. PMID: 33229445, PMCID: PMC8458060, DOI: 10.1136/gutjnl-2020-320805.Peer-Reviewed Original ResearchConceptsPrimary gastric cancerLymph node metastasisPrimary tumorGastric cancerIntratumour heterogeneityNode metastasisMatched lymph node metastasesRegional lymph node metastasisMultiplex ligation-dependent probe amplificationLigation-dependent probe amplificationPatient-matchedProgressive genomic changesDNA copy number profilesEndoscopic mucosal biopsiesCopy number profilesTherapeutically relevant genesLocoregional metastasesTumor disseminationResected samplesTargeted therapyHistomorphological phenotypesProbe amplificationBiomarker testingClinical trialsNanoString results
2024
State-of-the-Art Advancements in Gastroesophageal Cancer Treatment: Harnessing Biomarkers for Precision Care.
Balmaceda N, Petrillo A, Krishnan M, Zhao J, Kim S, Klute K, Sundar R. State-of-the-Art Advancements in Gastroesophageal Cancer Treatment: Harnessing Biomarkers for Precision Care. American Society Of Clinical Oncology Educational Book 2024, 44: e431060. PMID: 38771996, DOI: 10.1200/edbk_431060.Peer-Reviewed Original ResearchConceptsGastroesophageal cancerIntegration of immune checkpoint inhibitorsChimeric antigen receptor T cellsImmune checkpoint inhibitorsMetastatic gastroesophageal cancerPD-1 inhibitorsAdoptive cell therapyImmunotherapy-based approachesResectable gastroesophageal cancerAntibody-drug conjugatesCheckpoint inhibitorsPD-1Perioperative chemotherapyTargeted therapyT cellsTreatment paradigmFGFR2 inhibitorsCell therapyClinical challengeBispecific antibodiesImprove outcomesCancer treatmentReduced toxicityTherapyInhibitors
2020
The role of targeted therapy (TKI) in the treatment of advanced hepatocellular carcinoma (aHCC) in the era of immunotherapy: Real-world data using AI analytics from an academic medical center.
Wong R, Wu J, Leen A, Tey G, Asokumaran Y, Chan G, Siddappan C, Jeyasekharan A, Chee C, Yong W, Ngiam K, Sundar R. The role of targeted therapy (TKI) in the treatment of advanced hepatocellular carcinoma (aHCC) in the era of immunotherapy: Real-world data using AI analytics from an academic medical center. Journal Of Clinical Oncology 2020, 38: e16623-e16623. DOI: 10.1200/jco.2020.38.15_suppl.e16623.Peer-Reviewed Original ResearchAdvanced hepatocellular carcinomaEra of immunotherapySequence of therapySystemic therapyOverall survivalHCC patientsClinical outcomesManagement of advanced hepatocellular carcinomaTreated with first-line immunotherapyTreatment of advanced hepatocellular carcinomaFirst-line immunotherapyFirst-line TKIsSecond-line immunotherapySecond-line TKIsLoco-regional therapiesProgression-free survivalSecond-line therapySecond-line treatmentPillar of treatmentChild-Pugh scoreMinority of patientsSecond-lineFirst-lineMedian ageTargeted therapy
2017
Clinical Outcome of Patients with Advanced Biliary Tract Cancer in a Dedicated Phase I Unit
Sundar R, Custodio A, Petruckevich A, Chénard-Poirier M, Ameratunga M, Collins D, Lim J, Kaye S, Tunariu N, Banerji U, de Bono J, Lopez J. Clinical Outcome of Patients with Advanced Biliary Tract Cancer in a Dedicated Phase I Unit. Clinical Oncology 2017, 30: 185-191. PMID: 29224898, DOI: 10.1016/j.clon.2017.11.011.Peer-Reviewed Original ResearchConceptsAdvanced biliary tract carcinomaPhase I clinical trialPhase I unitABC patientsAdvanced biliary tract cancerMolecular characterisation of tumoursClinical outcomes of patientsClinical benefit rateBiliary tract carcinomaBiliary tract cancerComprehensive molecular profilingPhase I trialOutcomes of patientsCharacterisation of tumoursStable diseaseI unitsAdvanced diseaseI trialBenefit rateTargeted therapyTreatment detailsTrial discontinuationExceptional respondersPTEN lossClinical outcomes